Here, we provide a comprehensive study related to the risks of all biopharmaceutical firms going public in the USA between 1996 and 2015. We found 355 firms that met our requirements for being in the sector that focuses on creating drugs for humans. Collectively, these firms spent approximately US$86.9 billion on research and development (R&D) during this time. They also lost approximately US$69.3 billion in combined net income. We also examine the delisting of these firms from a public market, their number of collaborators at the initial public offering (IPO), and estimate the percentage ownership by other biopharmaceutical firms at the IPO.

中文翻译：

---

与新交易的生物制药公司相关的固有风险

在这里，我们提供了与1996年至2015年期间所有生物制药公司在美国上市的风险相关的综合研究。我们找到了355家满足我们在专注于为人类创造药物的行业中的要求的公司。在此期间，这些公司总计花费了大约869亿美元用于研发。他们也损失了大约693亿美元的净收入。我们还研究了这些公司在公开市场上的退市，首次公开募股（IPO）时其合作者的数量，并估计了其他生物制药公司在IPO时的持股比例。